Oh boy, a report that combines two of my favorite entities in the health care world–hospitals and drug companies. (PHAR Report) The report looks specifically at payments by private health plans for physician-administered drugs, with the administration occurring in a hospital outpatient setting. It is a well-known abusive practice for hospitals to employ or acquire physicians and then jack up prices for their services. This category of drugs, which tends to be very expensive and is often used for cancer, arthritis and similar serious conditions, has seen a lot of misuse in this regard. In addition to their general inclination to raise the prices for these medications, hospitals also sometimes get special pricing on them through programs like 340B, which lowers their cost and raises profits. According to the report, 47% of patients receiving a physician-administered drug get it in a doctor’s office and 53% in a hospital outpatient department. But hospitals keep 91% of all gross profits earned from the use of these drugs, while physicians get only 9%. Shows you how great the spread in prices must be. Furthermore, for every $100 spent on physician-administered drugs in the hospital setting, hospitals keep $58 while their cost, or the payment to the drugs’ manufacturer, represents only $42. That $58 is basically all profit to the hospital–the costs related to the labor, etc. involved in administering the drug is paid by a separate fee. So this is a line of business which is immensely profitable to hospitals, most of them supposedly non-profits, and which greatly raises costs to private health plans and to the members they serve, who often have extensive deductibles and copayments. If you are a member of a non-profit health system’s board, and supposedly representing the public interest, I don’t know how you sleep at nite. I know how the executives of these systems do–on pillows stuffed with cash from the excessive compensation they get as a result of the excessive prices the hospitals charge.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
November 30, 2023
How Are Family Finances Really Doing?
A detailed look at American family finances suggests that the wealthy are doing great but…
Commentary
November 30, 2023
Is the Economy “Strong”?
While the economy supposedly is cooking along, unsustainable government and consumer spending are the major…
Commentary
November 29, 2023
What Is Happening With Health Plans Globally?
Private health insurers globally face the same cost pressures as we do in the US,…